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Abstract. 
 
Urokinase-type plasminogen activator (uPA) 
activates the mitogen activated protein (MAP) kinases, 
extracellular signal-regulated kinase (ERK) 1 and 2, in 
diverse cell types. In this study, we demonstrate that 
uPA stimulates migration of MCF-7 breast cancer cells, 
HT 1080 ﬁbrosarcoma cells, and uPAR-overexpressing 
MCF-7 cells by a mechanism that depends on uPA re-
ceptor (uPAR)-ligation and ERK activation. Ras and 
MAP kinase kinase (MEK) were necessary and sufﬁ-
cient for uPA-induced ERK activation and stimulation 
of cellular migration, as demonstrated in experiments 
with dominant-negative and constitutively active mu-
tants of these signaling proteins. Myosin light chain ki-
nase (MLCK) was also required for uPA-stimulated 
cellular migration, as determined in experiments with 
three separate MLCK inhibitors. When MCF-7 cells 
were treated with uPA, MLCK was phosphorylated by 
a MEK-dependent pathway and apparently activated, 
since serine-phosphorylation of myosin II regulatory 
light chain (RLC) was also increased. Despite the tran-
sient nature of ERK phosphorylation, MLCK remained 
phosphorylated for at least 6 h. The uPA-induced in-
crease in MCF-7 cell migration was observed selec-
tively on vitronectin-coated surfaces and was mediated 
by a 
 
b
 
1
 
-integrin (probably 
 
a
 
V
 
b
 
1
 
) and 
 
a
 
V
 
b
 
5
 
. When
MCF-7 cells were transfected to express 
 
a
 
V
 
b
 
3
 
 and 
treated with uPA, ERK was still phosphorylated; how-
ever, the cells did not demonstrate increased migration. 
Neutralizing the function of 
 
a
 
V
 
b
 
3
 
, with blocking anti-
body, restored the ability of uPA to promote cellular 
migration. Thus, we have demonstrated that uPA pro-
motes cellular migration, in an integrin-selective man-
ner, by initiating a uPAR-dependent signaling cascade 
in which Ras, MEK, ERK, and MLCK serve as essen-
tial downstream effectors.
Key words: urokinase-type plasminogen activator • 
myosin light chain kinase • integrins • vitronectin • cel-
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U
 
ROKINASE
 
-type plasminogen activator (uPA)
 
1
 
 is a
serine proteinase which is synthesized as a 54-kD
single chain (sc) zymogen and converted into the
active two chain form (tcuPA) by various proteinases, in-
cluding plasmin (de Munk and Rijken, 1990). Both scuPA
and tcuPA bind with high affinity (
 
K
 
d
 
 of 0.1–1.0 nM) to
the cell-surface receptor, uPAR (Ellis and Dano, 1992).
Binding to uPAR may cause scuPA to express intrinsic
proteinase activity (Manchanda and Schwartz, 1991; Wang
et al., 1997), promote the conversion of scuPA to tcuPA
(Ellis et al., 1989), and accelerate the activation of cell-
associated plasminogen (Cohen et al., 1991; Ellis and
Dano, 1992). These reactions increase cell-surface protein-
ase activity, which may be important for cancer cell invasion
and metastasis in vivo (for review see Andreasen et al., 1997).
uPAR is linked to the cell surface by a glycosyl-phos-
phatidylinositol (GPI) anchor (Ploug et al., 1991) and thus
lacks transmembrane and intracytoplasmic domains. Nev-
ertheless, uPAR expresses multiple activities, unrelated to
proteinase localization, which regulate the interaction of
cells with the microenvironment. First, uPAR binds di-
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1. 
 
Abbreviations used in this paper:
 
 ERK, extracellular signal-regulated ki-
nase; GFP, green fluorescent protein; GPI, glycosyl-phosphatidylinositol;
HA, hemagglutinin; MAP kinase, mitogen activated protein kinase;
MEK, MAP kinase kinase; MLCK, myosin light chain kinase; PAI, plas-
minogen activator inhibitor; RLC, myosin II regulatory light chain; sc, sin-
gle chain; tc, two chain; uPA, urokinase-type plasminogen activator;
uPAR, urokinase-type plasminogen activator receptor. 
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rectly to vitronectin and in some cells may augment or
substitute for the function of 
 
a
 
V
 
-containing integrins (Wei
et al., 1994). uPAR also associates with integrins (Bo-
huslav et al., 1995; Simon et al., 1996; Sitrin et al., 1996;
Wei et al., 1996; Xue et al., 1997) and may, by direct inter-
action, modulate the function of specific 
 
b
 
1 
 
and 
 
b
 
2
 
 sub-
unit–containing integrins (Wei et al., 1994; Sitrin et al.,
1996; May et al., 1998). Finally, uPAR functions as a sig-
naling receptor, probably with the aid of a transmembrane
adaptor protein or multiprotein-complex which includes
integrins (Chapman, 1997).
The signaling cascades that are activated when uPA
binds to uPAR are only partially characterized. Known
protein tyrosine kinases in the 
 
Src
 
-family, including p60
 
fyn
 
,
p53/p56
 
lyn
 
, p56/p59
 
hck
 
, and p59
 
fgr
 
, have been coimmuno-
precipitated with uPAR (Dumler et al., 1993, 1998; Bo-
huslav et al., 1995; Resnati et al., 1996; Konakova et al.,
1998) and at least p56/p59
 
hck
 
 is activated by uPA (Resnati
et al., 1996; Konakova et al., 1998). uPA also activates pro-
tein kinase C
 
e
 
 (Busso et al., 1994), the JAK1/STAT1 sig-
naling pathway (Koshelnick et al., 1997; Dumler et al.,
1998), focal adhesion kinase (Tang et al., 1998), and the
mitogen activated protein (MAP) kinases, extracellular-
signal regulated kinase (ERK) 1 and 2 (Kanse et al., 1997;
Konakova et al., 1998; Nguyen et al., 1998; Tang et al.,
1998). The proteolytic activity of uPA is not required for
these signal transduction responses.
uPA promotes the migration of diverse cell types (Ode-
kon et al., 1992; Busso et al., 1994; Resnati et al., 1996;
Stefansson and Lawrence, 1996; Nguyen et al., 1998); how-
ever, it is not clear how the various activities of the uPA/
uPAR system are integrated to generate this response. In
MCF-7 breast cancer cells, activation of ERK is appar-
ently essential for uPA-promoted cellular migration since
the MAP kinase kinase (MEK) inhibitor, PD098059, com-
pletely blocks the uPA response without affecting the
basal level of cellular migration (Nguyen et al., 1998).
Once activated, ERK may translocate to the nucleus and
regulate gene expression by modifying transcription fac-
tors (Gille et al., 1992; Marais et al., 1993; Hipskind et al.,
1994; Hill and Treisman, 1995); however, ERK also modi-
fies multiple cytoplasmic substrates (Kanemitsu and Lau,
1993; Lin et al., 1993; Klemke et al., 1997). Klemke et
al.  (1997) demonstrated that ERK phosphorylates and
thereby activates myosin light chain kinase (MLCK), pro-
moting cellular migration. Activated ERK also suppresses
the function of specific integrins (Hughes et al., 1997) and
may promote rapid disassembly of focal contacts (Xie et al.,
1998), allowing more effective cytoskeletal contraction at
the rear of the migrating cell (for review see Lauffen-
berger and Horwitz, 1996).
The goal of this investigation was to elucidate the mech-
anism by which uPA promotes cellular migration. Our
results demonstrate that the uPA response requires
uPAR-ligation and activation of the Ras/ERK-signaling
pathway. MLCK functions downstream of Ras/ERK and
is also an essential mediator of uPA-promoted cellular mi-
gration, suggesting that the uPA/uPAR system may regu-
late cytoskeletal contractility. MCF-7 cell migration on vi-
tronectin was promoted by uPA only when migration was
under the control of 
 
a
 
V
 
b
 
5
 
 and a 
 
b
 
1
 
 subunit–containing in-
tegrin (probably 
 
a
 
V
 
b
 
1
 
), but not 
 
a
 
V
 
b
 
3
 
, thus defining yet an-
other novel functional relationship between integrins and
the uPA/uPAR system. The activity of MLCK in uPA-
promoted cellular migration and the integrin-selectivity of
the response suggest a model in which uPAR-initiated sig-
nal transduction orchestrates integrin function and cyto-
skeletal reorganization during cellular migration.
 
Materials and Methods
 
Antibodies and Reagents
 
scuPA and tcuPA were provided by Drs. Jack Henkin and Andrew Mazar
of Abbott Laboratories. tcuPA was inactivated with 20 mM diisopropyl-
fluorophosphate (Sigma Chemical Co.), as described previously (Nguyen
et al., 1998). In the resulting preparation (DIP-uPA), 
 
.
 
95% of the enzy-
matic activity of tcuPA was abolished, as determined by the hydrolysis
rate of the uPA-specific chromogenic substrate, 
 
L
 
-pyroglutamyl-glycyl-
arginine-
 
p
 
-nitroanilide HCl (Bachem). Type I collagen was from Collabo-
rative Biochemical Products. Vitronectin was purified according to the
method of Yatohgo et al. (1988). The expression vector, pEGFP, which
encodes green fluorescent protein (GFP), was from Clontech. Polyclonal
anti–human uPAR antibody 399R, which recognizes uPAR and blocks
uPA-binding to uPAR, and monoclonal anti–human uPA antibody, which
is directed against the growth factor domain of uPA, were from American
Diagnostica. In control experiments, we confirmed that each of these anti-
bodies, at 25 
 
m
 
g/ml, inhibits 
 
.
 
95% of the specific binding of 
 
125
 
I-DIP-uPA
to MCF-7 cells (data not shown). The two antibodies also blocked ERK1/2
phosphorylation in response to exogenously added scuPA in MCF-7 cells.
Polyclonal antibody specific for phosphorylated ERK1/2 was from
Promega or Calbiochem. Polyclonal antibodies which recognize total
ERK antigen and polyclonal antibodies which recognize phosphoser-
ine residues were from Zymed. Monoclonal anti-RLC antibody was
from ICN Biomedicals. Monoclonal anti-hemagglutinin (HA) antiserum
12CA5 was from Babco. MLCK-specific monoclonal antibody (clone
K36) was from Sigma Chemical Co. Integrin-specific blocking antibodies
directed against human 
 
a
 
V
 
b
 
5
 
 (P1F6), 
 
a
 
V
 
b
 
3
 
 (LM609), and 
 
b
 
1
 
-containing in-
tegrins (6S6) were from Chemicon International. The MEK inhibitor,
PD098059, the MLCK inhibitors, ML-7, ML-9, and W-7, and actinomycin
D were from Calbiochem. Calcein-AM was from Molecular Probes. Leu-
peptin was from Boehringer Mannheim. Cycloheximide, PMSF, aprotinin,
benzamidine, NaF, sodium orthovanadate, and G418 were from Sigma
Chemical Co.
 
Cell Culture and Transfection Methods
 
Low-passage MCF-7 cells were kindly provided by Dr. Richard Santen
(University of Virginia, Charlottesville, VA) and cultured in RPMI (Life
Technologies, Inc.) supplemented with 10% FBS (Hyclone), penicillin
(100 U/ml), and streptomycin (100 
 
m
 
g/ml) (Life Technologies, Inc.). HT
1080 human fibrosarcoma cells were from the ATCC. These cells were
cultured in MEM supplemented with FBS, penicillin, and streptomycin.
Cells were passaged with enzyme-free cell dissociation buffer and main-
tained in culture at 37
 
8
 
C for 48 h before conducting experiments.
The full-length human uPAR cDNA was obtained from the ATCC and
subcloned into pBK-CMV (Stratagene). To generate stable MCF-7 cell
lines which overexpress uPAR, 5 
 
3
 
 10
 
5
 
 cells were transfected with 2 
 
m
 
g of
the uPAR expression construct, using 10 
 
m
 
l of Superfect (Qiagen) for 2.5 h
at 37
 
8
 
C. The cells were then washed with serum-free RPMI, cultured in se-
rum-supplemented medium for 48 h, and selected in G418 (1 mg/ml) for
14 d. Single-cell clones were prepared by serial dilution and screened for
uPAR overexpression by flow cytometry. Cell-surface uPAR was quanti-
tated by measuring specific binding of 
 
125
 
I-DIP-uPA, as described previ-
ously (Nguyen et al., 1998). To determine the average mass of the MCF-7
cell, suspended cells were counted with a hemocytometer or Coulter
counter (yielding equivalent results) and then extracted for protein deter-
minations. The mean cellular mass was 0.94 
 
6 
 
0.07 ng (
 
n
 
 5 
 
5). This value
was used to calculate the number of copies of cell-surface uPAR/cell from
B
 
max
 
 values.
Expression constructs which encode constitutively active rat MEK1
(S218
 
®
 
D/S222
 
®
 
D) and dominant-negative rabbit MEK1 (S217
 
®
 
A), in
pCHA and pBABE, respectively, were described previously (Cowley
et al., 1994; Catling et al., 1995). Expression constructs which encode
constitutively active H-Ras (G12
 
®
 
V) and dominant-negative H-Ras 
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(S17
 
®
 
N), in pDCR, were described by White et al. (1995) and Cai et al.
(1990), respectively. MCF-7 cells (2 
 
3
 
 10
 
6
 
) were cotransfected with each
of these constructs (5.0 
 
m
 
g) and with 1.25 
 
m
 
g of pEGFP, using 30 
 
m
 
l of Su-
perfect. The cells were then maintained in culture for 24–36 h before anal-
ysis. Transfection efficiencies were 20–30%, as determined by fluores-
cence microscopy to detect GFP-positive cells. Cotransfection efficiencies
were determined by immunofluorescence microscopy. In these analyses,
cells were cotransfected with pEGFP and each of the four constructs,
fixed in 4% paraformaldehyde, permeabilized with 1.1% Triton X-100,
and incubated with a mouse monoclonal antibody (1:1,000) which recog-
nizes the HA epitope-tag. The cells were then washed and incubated with
Texas red–conjugated rabbit anti–mouse IgG (1:2,000, Vector Laborato-
ries). Cotransfection was demonstrated by the presence of Texas red fluo-
rescence and GFP fluorescence in the same cells and was always 
 
.
 
90%.
The full-length cDNA for the 
 
b
 
3
 
-integrin subunit was kindly provided
by Dr. David Cheresh (Scripps Research Institute, La Jolla, CA). The
cDNA was subcloned into pBK-CMV and transfected into MCF-7 cells (2 
 
m
 
g
cDNA/5 
 
3
 
 10
 
5
 
 cells) using 10 
 
m
 
l Superfect. The cells were cultured for 36–
48 h and selected in G418 (1 mg/ml) for 14 d. The transfectants were then
subjected to flow cytometry, using antibody LM609 and fluorescein-conju-
gated anti–mouse IgG, to detect cell-surface 
 
a
 
V
 
b
 
3
 
 expression. After flow
cytometry, the cells were cultured in RPMI supplemented with G418 (25
 
m
 
g/ml), FBS, penicillin, and streptomycin. ERK activation experiments
and migration assays were performed within 2 wk of obtaining flow cy-
tometry results.
 
ERK Activation in Transfected Cells
 
To confirm that ERK activity was regulated in cells transfected to express
mutant MEK1 or H-Ras, 5 
 
3
 
 10
 
5
 
 MCF-7 cells were transfected with 5 
 
m
 
g
of each cDNA construct and with 1.25 
 
m
 
g of a construct encoding HA-
tagged ERK1, as described by Chu et al. (1996). The cells were main-
tained in serum-supplemented medium for 24 h, serum-starved for 4 h,
and then treated with 10 nM DIP-uPA or with vehicle for 1 min. Cells
were extracted in RIPA buffer, which contains 0.1% SDS, 1% deoxycho-
late, 1% NP-40, 10 mM sodium phosphate, 150 mM NaCl, 2 mM EDTA,
50 mM NaF, 5 mM sodium pyrophosphate, 0.1 mM sodium vanadate, 2 mM
PMSF, 0.1 
 
m
 
g/ml leupeptin, and 100 KIU/ml aprotinin. HA-ERK1 was
immunoprecipitated using anti-serum 12CA5, as described previously
(Catling et al., 1995). Samples were then subjected to SDS-PAGE and
transferred to nitrocellulose. Phosphorylated HA-ERK1 and total HA-
ERK1 were detected by immunoblot analysis (Nguyen et al., 1998).
ERK phosphorylation, in 
 
b
 
3
 
-integrin subunit-expressing MCF-7 cells,
was also detected by immunoblot analysis. In brief, MCF-7 cells, that had
been transfected and selected, were transferred to serum-free medium for
6 h and then treated with 10 nM DIP-uPA, 25 ng/ml EGF, or vehicle. Cell
extracts were subjected to SDS-PAGE, transferred to nitrocellulose mem-
branes, and probed with antibodies for phosphorylated ERK1/2 and total
ERK1/2, as described previously (Nguyen et al., 1998).
 
MLCK Phosphorylation Experiments
 
MCF-7 cells were cultured in 100-mm dishes until 70–80% confluent,
washed with phosphate-free RPMI, and metabolically labeled for 2 h at
37
 
8
 
C with [
 
32
 
P]orthophosphate (250 
 
m
 
Ci) in serum-free RPMI supple-
mented with 1 mg/ml BSA and 1 mg/ml sodium orthovanadate. The la-
beled cells were treated with 10 nM DIP-uPA for up to 6 h. Control cells
were treated with vehicle instead of DIP-uPA. In some cultures, 50 
 
m
 
M
PD098059 was added to inhibit MEK. The PD098059 was added 15 min
before adding the DIP-uPA and remained present throughout the assay.
After washing the cultures, the cells were extracted with 1% NP-40, 10 mM
Tris-HCl, 140 mM NaCl, 2 mM EDTA, 100 KIU/ml aprotinin, 0.1 mg/ml
leupeptin, 2 mM PMSF, 50 mM NaF, 1 mM sodium vanadate, 20 mM so-
dium pyrophosphate, pH 8.1, for 30 min on ice and centrifuged at 800 
 
g
 
 for
10 min. The supernatants were precleared with protein A–agarose for 1 h
at 22
 
8
 
C. MLCK in the supernatants was then immunoprecipitated by incu-
bation with MLCK-specific monoclonal antibody (6 
 
m
 
g) for 12 h at 4
 
8
 
C,
rabbit anti–mouse IgG (7.5 
 
m
 
g) for 4 h at 4
 
8
 
C, and finally with protein
A–agarose for 1 h at 22
 
8
 
C. The immunoprecipitates were subjected to
SDS-PAGE on 8% acrylamide slabs and transferred to nitrocellulose.
Phosphorylated MLCK was detected by autoradiography.
 
Serine-phosphorylation of RLC
 
Suspended MCF-7 cells (10
 
5
 
 in 100 
 
m
 
l) were treated with 10 nM DIP-uPA
or with vehicle for the indicated times at 37
 
8
 
C. Reactions were terminated
by adding SDS sample buffer at 95
 
8
 
C. The whole-cell lysates were then
subjected to SDS-PAGE on 15% acrylamide slabs and transferred to ni-
trocellulose. Immunoblot analysis was performed to detect serine-phos-
phorylated RLC (primary antibody at 0.5 
 
m
 
g/ml). The same blots were
also probed to detect total RLC. In some experiments, the cells were pre-
treated for 15 min with drugs that inhibit MEK or MLCK, before adding
uPA or vehicle.
 
Migration Assays
 
We demonstrated previously that uPA promotes MCF-7 cell migration
across serum-coated Transwell membranes irrespective of whether both
sides of the membrane are coated with serum or just the underside
(Nguyen et al., 1998). The magnitude of the uPA response was greater
when both sides of the membrane were serum-coated; however, coating
just the underside allows for more rapid cellular migration so that experi-
ments may be completed in 6 h. For this reason, the single-sided coating
method was used in this study.
Transwell membranes (6.5 mm, 8.0-
 
m
 
m pores) (Costar) were coated
with 20% FBS, purified vitronectin (5 
 
m
 
g/ml), or type I collagen (25 
 
m
 
g/ml)
for 2 h at 37
 
8
 
C. Both membrane surfaces were blocked with 10 mg/ml
BSA. MCF-7 cells, uPAR-overexpressing MCF-7 cells, and 
 
b
 
3
 
-integrin
subunit-expressing MCF-7 cells (10
 
5
 
 cells in 100 
 
m
 
l) were pretreated with
10 nM DIP-uPA or with vehicle for 15 min, in suspension, and then added
to the top chamber. Before DIP-uPA exposure, some cells were treated
for 15 min with actinomycin D (10 
 
m
 
g/ml), cycloheximide (3 
 
m
 
g/ml), ML-7
(3 
 
m
 
M), ML-9 (30 
 
m
 
M), W-7 (51 
 
m
 
M), or with the following antibodies:
uPA-specific antibody, uPAR-specific antibody, LM609, P1F6, or 6S6 (at
concentrations up to 32 
 
m
 
g/ml). When cells were pretreated with DIP-
uPA, 10 nM DIP-uPA was added to both Transwell chambers. Drugs or
antibodies were added to the top chamber. The bottom chamber always
contained 10% FBS. After terminating a study, cells were removed from
the top surface of each membrane using a cotton swab. Cells which pene-
trated to the underside surfaces of the membranes were stained with Diff-
Quik (Dade Diagnostics) and counted. In some experiments, migration of
uPAR-overexpressing MCF-7 cells was quantitated by fixing the mem-
branes in methanol and staining the migratory cells with 0.1% crystal vio-
let. The dye was eluted with 10% acetic acid and the absorbance of the
eluate was determined at 600 nm. In control experiments, we confirmed
that crystal violet absorbance is linearly related to cell number.
HT 1080 cell migration was studied in Transwell chambers containing
membranes that were coated on both surfaces with 20% FBS. 5 
 
3
 
 10
 
5
 
 cells
were added to the top chamber in serum-free medium and allowed to mi-
grate for 6 h in the presence or absence of 10 nM DIP-uPA. FBS was not
added to the bottom chamber. Thus, there was no chemotactic or hapto-
tactic stimulus, suggesting that chemokinesis was detected. Nonmigrating
cells were removed with a cotton swab. Cellular migration was then deter-
mined by the crystal violet–staining method.
To study the migration of GFP-expressing cells, translucent Biocoat
Cell Culture Inserts (Becton Dickinson) were used instead of Transwell
chambers. The insert membranes had 8-
 
m
 
m pores and were coated with
serum or purified vitronectin. The response to uPA was not affected in
this alternative system as determined by counting Diff-Quik–stained cells.
Cells (5 
 
3
 
 10
 
5
 
) that were cotransfected with signaling effector mutants and
pEGFP, or with pEGFP alone, were added to the top chamber and al-
lowed to migrate for 6 h. In some experiments, cells were treated with in-
hibitors or antibodies and allowed to migrate in the presence or absence
of DIP-uPA. Migrating cells were fixed in 4% paraformaldehyde and
counted by fluorescence microscopy. To standardize results obtained with
transfected and untransfected cells, the pEGFP-transfection efficiency
was determined for each experiment. The number of GFP-positive cells
which migrated across the membrane was then divided by the transfection
efficiency (typically 0.2–0.3).
 
Mannosamine Treatment Protocol
 
Mannosamine inhibits a critical enzyme involved in the attachment of
GPI-linked proteins to their anchors (Lisanti et al., 1991) and can be used
to substantially downregulate the level of cell-surface uPAR (Wei et al.,
1994; Weaver et al., 1997). MCF-7 cells were treated with 10 mM man-
nosamine for 6 h at 37
 
8
 
C in glucose-free RPMI. Control cells were incu-
bated in glucose-free RPMI for the equivalent period of time. The cells
were then dissociated and added to Transwell chambers in the presence or
absence of mannosamine. In control experiments, MCF-7 cells that were
mannosamine-treated demonstrated unaltered Trypan blue exclusion. 
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Cell Adhesion Assays
 
Vitronectin-coated cell culture wells were prepared by incubating purified
vitronectin (5 mg/ml) in 96-well cell culture plates (Costar) for 2 h at 378C.
The wells were then blocked with BSA. MCF-7 cells that were cotrans-
fected to express GFP and dominant-negative or constitutively active
MEK1 or H-Ras (105 cells in 100 ml) were allowed to adhere for the indi-
cated times at 378C. To assess cellular adhesion, the wells were washed
with 10 mM Hepes, 150 mM NaCl, pH 7.4, and adherent cells were quanti-
tated by fluorescence emission. The excitation and emission wavelengths
were 488 nm and 507 nm, respectively. Fluorescence emission was also de-
termined for the total number of cells added to each well. Cellular adhe-
sion was quantitated as a percentage of the total number of GFP-express-
ing cells added. In control experiments, we determined that cell adhesion
and spreading do not affect fluorescence emission.
MCF-7 cells that did not express GFP were allowed to adhere to vi-
tronectin-coated cell culture wells in the presence of integrin-specific anti-
bodies (P1F6, LM609, 6S6) or drugs that inhibit MEK or MLCK. After
washing, adherent cells were stained with Calcein-AM (Braut-Boucher
et al., 1995) and quantitated by fluorescence emission using a Cytofluor
2350.
Results
uPA-stimulated Cellular Migration Is Antagonized by 
uPAR-specific Antibody and by PD098059 in Parent 
and uPAR-overexpressing MCF-7 Cells
We demonstrated previously that uPA activates ERK1/2,
rapidly but transiently, in MCF-7 cells and stimulates
MCF-7 cell migration (Nguyen et al., 1998). The selective
MEK inhibitor, PD098059, blocked the ability of uPA to
stimulate MCF-7 cell migration without affecting the basal
level of cellular migration, suggesting that ERK activation
is essential in the pathway by which uPA increases MCF-7
cell motility. Fig. 1 A confirms and extends our original
observations by demonstrating that DIP-uPA (10 nM) in-
creases MCF-7 cell migration, in serum-coated Transwells,
and that this activity is blocked by antibodies (25 mg/ml)
which bind to uPA or uPAR and prevent uPAR ligation.
The uPA- and uPAR-specific antibodies did not affect
MCF-7 cell migration in the absence of exogenously added
uPA. Furthermore, nonimmune IgG did not affect MCF-7
cell migration, in the presence or absence of uPA. Thus,
the motility-stimulating activity of uPA, in MCF-7 cells,
requires uPA-binding to uPAR.
MCF-7 cells express 3,300 copies of cell-surface uPAR,
as determined by 125I-DIP-uPA binding and the experi-
mentally determined mean cellular mass (0.94 ng) (Nguyen
et al., 1998). To further test the role of ERK activation
in uPA-promoted cellular migration, we overexpressed
uPAR in MCF-7 cells. Single-cell cloning yielded several
cell lines with increased levels of cell-surface uPAR, as de-
termined by flow cytometry. Clone M5 demonstrated in-
creased specific binding of 125I-DIP-uPA. The Kd (1.2 6
0.3 nM) was unchanged compared with that determined
for untransfected MCF-7 cells; however, the Bmax was in-
creased to 33 6 5 fmol/mg cell protein (n 5 4), corre-
sponding to 19,800 copies of cell-surface uPAR/cell (data
not shown). Fig. 1 B shows the results of migration experi-
ments performed with clone M5. In the absence of uPA,
the basal rate of M5 cell migration was 536 6 80 cells/
membrane (compared with 98 6 4 untransfected MCF-7
cells/membrane); however, basal M5 cell migration was
not inhibited by uPA- or uPAR-specific antibody or
PD098059. Thus, the increase in basal M5 cell migration
did not result from the binding of endogenously produced
uPA to uPAR or uPAR-initiated cell signaling as antici-
pated, since MCF-7 cells produce very low levels of uPA
(Nguyen et al., 1998; Webb et al., 1999). When treated
with DIP-uPA (10 nM), M5 cell migration increased 2.0 6
0.2-fold. The response to DIP-uPA was totally inhibited
by uPA- and uPAR-specific antibodies and by PD098059.
M5 cell migration was also analyzed by crystal violet stain-
ing instead of direct cell counts; DIP-uPA increased cellu-
lar migration 2.5 6 0.2-fold in these experiments (results
not shown). Thus, uPAR-overexpressing MCF-7 cells re-
spond similarly to the parent cells when treated with uPA.
uPA-stimulated HT 1080 Cell Migration Requires
ERK Activation
HT 1080 fibrosarcoma cells express uPAR (Laug et al.,
1992) and demonstrate increased levels of activated ERK2
when treated with uPA (Konakova et al., 1997). In our ini-
tial experiments, we demonstrated specific binding of 125I-
Figure 1. uPA promotes cellular migration by a uPAR-depen-
dent mechanism which is inhibited by PD098059 in parent and
uPAR-overexpressing MCF-7 cells. Each of the designated cell
types was treated with 10 nM DIP-uPA (1) or with vehicle (2)
and allowed to migrate for 6 h on serum-coated Transwell mem-
branes. Some cells were treated with uPA-specific antibody,
uPAR-specific antibody, nonimmune IgG (each at 25 mg/ml), or
with PD098059 (50 mM). Cellular migration is expressed as a per-
centage of that observed with control cells, which were not
treated with DIP-uPA, antibodies, or PD098059 (mean 6 SEM,
n 5 4).Nguyen et al. MLCK in uPA-promoted Cellular Migration 153
DIP-uPA to HT 1080 cells; the Kd was 1.2 6 0.4 nM and
the Bmax was 49 6 4 fmol/mg of cell protein (n 5 4), corre-
sponding to z30,000 copies of cell-surface uPAR/cell. In
Transwell assays, DIP-uPA (10 nM) increased HT 1080
cell migration 2.6 6 0.1-fold (Fig. 2 A). The effects of DIP-
uPA on HT 1080 cell migration were blocked by uPA- and
uPAR-specific antibody and by PD098059. The same re-
agents did not affect HT 1080 cell migration in the absence
of exogenously added uPA. Thus, uPAR-initiated signal
transduction and ERK activation are critical for uPA-
stimulated HT 1080 cell migration.
The lack of an effect of uPA- and uPAR-specific anti-
bodies on HT 1080 cell migration, in the absence of exoge-
nously added DIP-uPA, suggested that endogenously
produced uPA is insufficient to activate autocrine uPAR-
signaling in these cells. However, others have demon-
strated that HT 1080 cells express substantial levels of
uPA (Tsuboi and Rifkin, 1990; Laug et al., 1992). To ad-
dress this issue, we measured the concentration of uPA in
medium that was conditioned by HT 1080 cells for 24 h,
using an activity assay which detects scuPA and tcuPA
(Weaver et al., 1997). The uPA concentration was 24 6
4 pM. The activity assay does not detect uPA-PAI-1
complex; however, immunoblotting experiments demon-
strated only trace levels of this complex in the conditioned
medium (data not shown). As determined by the equation
for fractional receptor saturation Y 5 L/(Kd 1 L), a uPA
concentration of 24 pM would be expected to occupy no
more than 2% of the uPAR. In separate experiments, HT
1080 cells were incubated with 1 nM DIP-uPA at 48C. The
cells were then extracted and subjected to immunoblot
analysis to detect total cellular uPA (Fig. 2 B). Trace levels
of endogenously produced uPA were detected in extracts
from control cells which had not been treated with DIP-
uPA; this uPA may have been surface-associated or con-
tained within intracellular pools. The high molecular mass
band in the same lane is probably cell-associated uPA-
PAI-1 complex. After incubation with 1 nM DIP-uPA for
4 h at 48C, the amount of cell-associated uPA was sub-
stantially increased. Furthermore, uPAR-specific antibody
blocked the increase in uPA recovery. These studies dem-
onstrate that the majority of the uPAR, in HT 1080 cells, is
unliganded and available to bind exogenous DIP-uPA un-
der our experimental conditions.
MEK Is Essential in the uPAR-initiated Signaling 
Pathway which Increases MCF-7 Cell Migration
To further explore the relationship between the uPA/
uPAR system and ERK activation in promoting cellular
migration, we transfected MCF-7 cells to express domi-
nant-negative or constitutively active MEK1. To demon-
strate that the MEK1 mutants were functional as up-
stream-modulators of ERK activation, MCF-7 cells were
cotransfected to express HA-tagged ERK1. The transfec-
tants were treated with DIP-uPA (10 nM) or vehicle for 1
min; cell extracts were immunoprecipitated using an anti-
body directed against the HA-epitope and phosphorylated
ERK1 was detected by immunoblot analysis. As shown in
Fig. 3 A, MCF-7 cells that were transfected to express
dominant-negative MEK1 did not contain detectable lev-
els of phosphorylated HA-ERK1, irrespective of whether
these cells were treated with DIP-uPA or not. By contrast,
substantial levels of phosphorylated HA-ERK1 were de-
tected in cells that were transfected to express constitu-
tively active MEK1. However, when these cells were
treated with DIP-uPA, no further increase in phosphory-
lated HA-ERK1 was observed. As a control, we cotrans-
fected MCF-7 cells with the HA-tagged ERK1 construct
and with the empty vector (pCHA) which had been used
to prepare the constitutively active MEK1 mutant. In the
absence of uPA, only trace levels of phosphorylated HA-
ERK1 were observed; however, DIP-uPA substantially in-
creased phosphorylated HA-ERK1 in these cells. These
results demonstrate that the MEK1 mutants were func-
tional as regulators of ERK activation in the presence and
absence of uPA.
To study the migration of MCF-7 cells, which were tran-
Figure 2. uPA-stimulated HT 1080 cell migration requires ERK
activation and uPAR ligation. (A) HT 1080 cells were treated
with 10 nM DIP-uPA (1) or with vehicle (2) and allowed to mi-
grate for 6 h on serum-coated Transwell membranes. Some cells
were treated with uPA-specific antibody, uPAR-specific anti-
body (each at 25 mg/ml), or PD098059 (50 mM). Cellular migra-
tion is expressed as a percentage of that observed with control
cells that were not treated with DIP-uPA, antibodies, or inhibi-
tors. (B) HT 1080 cells (2.5 3 105 cells) were incubated with 1 nM
DIP-uPA or with vehicle for 4 h at 48C as indicated. Some cells
were pretreated with uPAR-specific antibody (25 mg/ml) for 20
min and then with DIP-uPA in the presence of antibody. HT
1080 cell detergent-extracts were subjected to SDS-PAGE on
8% slabs and transferred to nitrocellulose. Total cell-associated
uPA (endogenously produced and exogenously added) was de-
tected by immunoblot analysis, using uPA specific antibody
(1:10,000), and HRP-conjugated anti–mouse IgG (Sigma,
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siently transfected to express mutant forms of MEK1, we
cotransfected the cells with pEGFP. Cotransfection effi-
ciencies were always .90%, allowing us to selectively de-
tect the migration of transfected cells by GFP fluores-
cence. As shown in Fig. 3 B, cells that were transfected
only with pEGFP demonstrated increased migration when
treated with 10 nM DIP-uPA. When MCF-7 cells were
transfected to express dominant-negative MEK1, basal
migration was not significantly altered (24% decrease, P .
0.1); however, the ability of uPA to stimulate cellular
migration was entirely blocked. MCF-7 cells that were
transfected to express constitutively active MEK1 dem-
onstrated increased migration in the absence of uPA; how-
ever, these cells demonstrated no change in migration
when treated with DIP-uPA. Since uPAR synthesis may
be regulated by a MAP kinase–dependent pathway (Tka-
chuk et al., 1996), control experiments were performed to
rule out the possibility that increased uPAR expression
was responsible for the increase in the migration of consti-
tutively active MEK1-expressing cells. First, GFP-express-
ing cells were isolated by flow cytometry and studied in
125I-DIP-uPA-binding experiments; no change in cell-sur-
face uPAR was detected (data not shown). Furthermore,
migration of constitutively active MEK1-expressing MCF-7
cells was not inhibited by uPA- or uPAR-specific antibod-
ies (data not shown). Thus, active MEK operates down-
stream of uPAR, as a necessary and sufficient effector in
the signal transduction pathway by which uPA stimulates
MCF-7 cell migration.
In Transwell migration assays, increased cellular migra-
tion may reflect increased cellular penetration of the Trans-
well membranes or a change in the kinetics of cellular ad-
hesion to the membranes. To rule out the latter possibility,
GFP-expressing MCF-7 cells were allowed to adhere to
vitronectin-coated cell culture wells for 10, 20, 30, 40, or 60
min. Adhesion was detected by measuring fluorescence
emission in a Cytofluor 2350. The kinetics of MCF-7 cell
adhesion were not affected by DIP-uPA or by either MEK
mutant (data not shown). PD098059 also did not affect
MCF-7 cell adhesion, in the presence or absence of uPA.
Thus, the differences observed in the Transwell assays re-
flect changes in the migration of cells which have already
adhered to the Transwell membranes.
Ras Is Essential in the uPAR-initiated Signaling 
Pathway which Increases MCF-7 Cell Migration
Ras activation is frequently but not always necessary as an
upstream activator of ERK in growth factor–stimulated
cells (Frost et al., 1997). To test whether Ras is involved in
the uPAR-initiated signaling pathway which leads to ERK
activation, MCF-7 cells were cotransfected to express
HA-tagged ERK1 and either dominant-negative H-Ras or
constitutively active H-Ras. As shown in Fig. 4 A, phos-
phorylated HA-ERK1 was not detected in cells that were
transfected to express dominant-negative H-Ras, irrespec-
tive of whether the cells were treated with uPA or not. By
contrast, cells that were transfected to express constitu-
tively active H-Ras demonstrated substantial levels of
phosphorylated HA-ERK1; however, the level of phos-
phorylated HA-ERK1 was not further increased by uPA.
As a control, we transfected cells with the empty vector,
pDCR. Trace levels of phosphorylated HA-ERK1 were
detected in the absence of uPA; however, when these cells
were treated with DIP-uPA, a substantial increase in
phosphorylated HA-ERK1 was observed. In other con-
trol experiments, we demonstrated unchanged binding of
125I-DIP-uPA to constitutively active H-Ras–expressing
MCF-7 cells, indicating that cell-surface uPAR expression
is not altered in these cells (data not shown).
To determine whether the H-Ras mutants affect the
ability of uPA to stimulate cellular migration, MCF-7 cells
were cotransfected to express GFP. As shown in Fig. 4
B, MCF-7 cells that expressed dominant-negative H-Ras
demonstrated only a slight decrease in migration in the ab-
sence of uPA, which was not statistically significant. How-
ever, these cells failed to demonstrate increased migration
Figure 3. MEK is required for uPA-induced MAP kinase activa-
tion and motility stimulation. (A) MCF-7 cells were cotrans-
fected to express HA-tagged ERK1 and the specified MEK mu-
tants or the empty vector, pCHA. HA-tagged ERK1 was
immunoprecipitated from cell extracts 1 min after treating the
cells with 10 nM DIP-uPA (1) or with vehicle (2). Phosphory-
lated and total levels of ERK1 were determined by immunoblot
analysis. (B) MCF-7 cells were transfected to express the speci-
fied MEK mutants and GFP, or GFP alone (pEGFP). Mock-
transfected cells were treated with Superfect in the absence of
cDNAs. Cells were allowed to migrate in the presence (1) or ab-
sence (2) of 10 nM DIP-uPA for 6 h on serum-coated mem-
branes. Cellular migration of transfected cells was determined us-
ing fluorescence microscopy to detect GFP-expressing cells.
Migration of mock-transfected cells was determined by Diff-
Quik staining. Mock-transfected cells migrated identically to
MCF-7 cells that were not Superfect-treated, in the presence and
absence of uPA (data not shown). To compare results obtained
with GFP-expressing and mock-transfected cells, the number of
GFP-expressing cells that penetrated the membrane was divided
by the transfection efficiency. For each bar, cellular migration is
expressed as a percentage of that observed with mock-trans-
fected cells that were not treated with DIP-uPA.Nguyen et al. MLCK in uPA-promoted Cellular Migration 155
when treated with DIP-uPA. MCF-7 cells that expressed
constitutively active H-Ras demonstrated 2.3 6 0.3-fold
increased migration in the absence of uPA, but no further
increase in motility when DIP-uPA was added. Antibodies
against uPA and uPAR had no effect on the migration of
constitutively active H-Ras–expressing MCF-7 cells (data
not shown). Thus, constitutively active H-Ras did not in-
crease migration by regulating uPA or uPAR expression.
Instead, Ras functioned as an essential mediator of the
uPAR-initiated signal transduction response which stimu-
lates MCF-7 cell migration.
uPA-stimulated MCF-7 Cell Migration Does Not 
Require New Gene Transcription or Protein Synthesis
When activated, ERK may translocate to the nucleus and
regulate gene expression by modifying transcription fac-
tors, such as Elk-1 (Gille et al., 1992; Marais et al., 1993;
Hill and Treisman, 1995). To determine whether new gene
transcription and/or protein synthesis are required for
uPA-stimulated MCF-7 cell migration, Transwell assays
were performed in the presence of actinomycin D or cy-
cloheximide (Fig. 5). Neither agent had any effect on the
migration of MCF-7 cells, in 6 h, in the absence of uPA.
Furthermore, cycloheximide and actinomycin D did not
affect the response of cells to DIP-uPA. In control experi-
ments, we demonstrated that [35S]methionine incorpora-
tion into total cellular protein was inhibited by .90%
when MCF-7 cells were cultured in the presence of 3 mg/ml
cycloheximide for 1–6 h (data not shown). We also demon-
strated that cycloheximide and actinomycin D do not sig-
nificantly affect the migration of MCF-7 cells that are
transfected to express constitutively active MEK1 (115 6
18% and 112 6 20% of control, respectively) or H-Ras
(107 6 5% and 89 6 17% of control, respectively). These
results demonstrate that ERK promotes MCF-7 cell mi-
gration in uPA-stimulated cells by a transcription-inde-
pendent pathway.
MLCK Is Phosphorylated and Activated by a
MEK-dependent Pathway in uPA-treated Cells
MLCK is a Ca21/calmodulin-dependent kinase that phos-
phorylates RLC, promoting contraction of the actin-based
cytoskeleton (Lamb et al., 1988; Goeckeler and Wysol-
merski, 1995). Several enzymes, including cyclic AMP–
dependent protein kinase, protein kinase C, and Ca21/
calmodulin-dependent protein kinase II, phosphorylate
MLCK near the calmodulin-binding domain, increasing
the concentration of Ca21 required for MLCK activation
and thereby effectively decreasing MLCK activity (for re-
views see Adelstein et al., 1982; Stull et al., 1993). p21-acti-
vated kinase also decreases MLCK activity by directly af-
fecting the enzyme Vmax (Sanders et al., 1999). However,
Klemke et al. (1997) demonstrated that ERK phosphory-
lates and thereby activates MLCK and that this reaction
may be critical in growth factor or integrin-initiated path-
ways which lead to accelerated cellular migration.
To determine whether uPAR-initiated signal transduc-
tion results in MLCK phosphorylation, MLCK was immu-
Figure 4. Ras is required for uPA-induced MAP kinase activa-
tion and MCF-7 cell migration. (A) MCF-7 cells were cotrans-
fected to express HA-tagged ERK1 and dominant-negative
H-Ras, constitutively active H-Ras, or the empty vector, pDCR.
The cells were then treated with 10 nM DIP-uPA (1) or vehicle
(2) for 1 min. HA-tagged ERK1 was recovered by immunopre-
cipitation. Phosphorylated and total levels of ERK1 were deter-
mined by immunoblot analysis. (B) MCF-7 cells were transfected
to express the specified H-Ras mutants and GFP or GFP alone.
The cells were then treated with 10 nM DIP-uPA (1) or vehicle
(2) and allowed to migrate for 6 h on serum-coated membranes.
Cellular migration was standardized to that observed with mock-
transfected cells that were not uPA-treated.
Figure 5. Gene transcription and protein synthesis are not re-
quired for uPA-promoted MCF-7 cell migration. MCF-7 cells
were allowed to migrate for 6 h on serum-coated Transwell mem-
branes in the presence (1) or absence (2) of 10 nM DIP-uPA.
Some MCF-7 cells were treated with cycloheximide (3 mg/ml) or
actinomycin D (10 mg/ml). Cellular migration is expressed as a
percentage of that observed with control cells that were not
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noprecipitated from MCF-7 cells that had been metaboli-
cally labeled with [32P]orthophosphate and treated with
DIP-uPA. Fig. 6 A shows that MLCK was phosphorylated
within 1 h of exposure to uPA; however, unlike ERK1/2,
MLCK phosphorylation was sustained for at least 6 h.
PhosphorImager analysis was used to quantitate phosphor-
ylated MLCK. When the results were standardized for to-
tal MLCK recovery, we did not detect significant variation
in the level of phosphorylated MLCK between 1 and 6 h
(Fig. 6 B). Pretreatment of MCF-7 cells with PD098059,
before DIP-uPA exposure, blocked MLCK phosphoryla-
tion. Thus, uPA-induced MLCK phosphorylation is MEK-
dependent. We have demonstrated that purified ERK1 di-
rectly phosphorylates MLCK in vitro (data not shown),
confirming the work of others (Klemke et al., 1997; Wu et al.,
1998); however, in intact uPA-treated cells, MLCK may be
phosphorylated directly by ERK or by another kinase
which is downstream of MEK.
To determine whether MLCK, which is phosphorylated
in uPA-treated cells, is also activated, we examined RLC
phosphorylation in whole-cell extracts using an antibody
which is specific for phosphoserine. As shown in Fig. 6 C,
the major serine-phosphorylated species demonstrated an
apparent mass of 23 kD. This species was identical in mo-
bility to RLC, as determined by probing the same blots
with RLC-specific antibody. DIP-uPA significantly in-
creased RLC phosphorylation. In five separate experi-
ments, the increase in RLC phosphorylation was 2.4 6
0.2-fold and 3.0 6 0.4-fold after treatment with 10 nM
DIP-uPA for 45 and 60 min, respectively. A number of
enzymes may phosphorylate RLC on serine, in addition to
MLCK (Bresnick, 1999); however, the increase in RLC
phosphorylation was blocked by the specific MLCK inhib-
itors, ML-7 (3 mM) and ML-9 (30 mM), and by the gen-
eral antagonist of Ca21/calmodulin-dependent kinases, W-7
(51 mM) (Table I). Each of these inhibitors was present at
a concentration that was 10-fold higher than the reported
Ki value for MLCK inhibition (Saitoh et al., 1987).
PD098059 also blocked the increase in RLC phosphoryla-
tion, suggesting a dependency on MEK activity. In experi-
ments that are not shown, increased RLC phosphorylation
was also demonstrated in uPA-treated cells by isoelectric
focusing, using the method described by Garcia et al.
(1995). These results support the conclusion that MLCK is
activated when phosphorylated by ERK, as proposed by
Klemke et al. (1997). Interestingly, none of the MLCK in-
hibitors significantly decreased RLC phosphorylation, in
the absence of uPA, when analyzed by phosphoserine im-
munoblotting 75 min after adding the drugs.
MLCK Activity Is Necessary for uPA-promoted 
Cellular Migration
To determine whether MLCK activity is necessary for
uPA-promoted MCF-7 cell migration, Transwell assays
were performed in the presence of the MLCK inhibitors.
In the absence of uPA, ML-7 and ML-9, at concentrations
up to 10-fold the reported Ki values for MLCK inhibition,
had little or no effect on MCF-7 cell migration (Fig. 7 A).
W-7 was also inactive at concentrations up to 51 mM,
which is 10-fold the reported Ki for MLCK inhibition.
These results suggest that MLCK activity is not essential
Figure 6. MLCK and RLC are phosphorylated in uPA-treated
MCF-7 cells. (A) MCF-7 cells were metabolically labeled with
[32P]orthophosphate and then treated with vehicle (control) or
with 10 nM DIP-uPA for the indicated times. Some MCF-7 cells
were treated with 50 mM PD098059 (1), beginning 15 min before
adding uPA and continuing for the entire assay. MLCK was im-
munoprecipitated from detergent extracts, subjected to SDS-
PAGE, and analyzed by autoradiography. (B) Densitometry was
performed using low-exposure autoradiography films from the
specified number of experiments (n 5 2–4). In each study, phos-
phorylated MLCK was not readily detected in the absence of
uPA. Thus, band intensity was standardized against that ob-
served with cells that had been treated with DIP-uPA for 1 h. (C)
Suspended MCF-7 cells were treated with 10 nM DIP-uPA or
with vehicle (control) for the indicated times. Cells lysates were
subjected to SDS-PAGE and immunoblot analysis to detect RLC
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for basal MCF-7 cell migration. W-7, at concentrations ex-
ceeding 0.1 mM, blocked MCF-7 cell migration, probably
reflecting the ability of W-7 to inhibit Ca21/calmodulin-
dependent kinases other than MLCK (Hidaka et al., 1981,
1988).
When MCF-7 cells were treated with DIP-uPA, in the
presence of the MLCK inhibitors, the uPA-induced in-
crease in cellular migration was blocked (Fig. 7 B). Equiv-
alent results were obtained in experiments with uPAR-
overexpressing MCF-7 cells and HT 1080 cells. None of
three drugs affected the basal level of migration of these
two cell lines; however, uPA-stimulated cellular migration
was inhibited. In control experiments, ML-7, ML-9, and
W-7 had no effect on MCF-7 cell adhesion to vitronectin
(data not shown). These studies demonstrate a critical role
for MLCK activity in uPA-stimulated cellular migration in
three distinct model systems.
uPA-promoted MCF-7 Cell Migration Is
Matrix Protein–selective
When surfaces are coated with serum, vitronectin serves as
the major attachment and spreading factor (Hayman et al.,
1985). To determine whether uPA-promoted MCF-7 cell
migration is matrix protein–selective, Transwell mem-
branes were coated with purified vitronectin or type I col-
lagen, instead of serum. DIP-uPA increased MCF-7 cell
migration on vitronectin 3.1 6 0.2-fold (n 5 5), as antici-
pated (Fig. 8). MCF-7 cells migrated more rapidly on type
I collagen-coated surfaces, in the absence of uPA; how-
ever, DIP-uPA failed to stimulate cellular migration fur-
ther. In control experiments, we demonstrated that MCF-7
cell migration across collagen-coated membranes occurs
as a linear function of time (1–6 h), precluding the possibil-
ity that we missed a uPA response due to the assay time
(data not shown).
Mannosamine inhibits the membrane-anchoring of all
GPI-linked proteins, including uPAR (Lisanti et al., 1991;
Wei et al., 1994; Weaver et al., 1997). When MCF-7 cells
were treated with mannosamine, cellular migration across
type I collagen-coated membranes was not significantly af-
fected. By contrast, mannosamine substantially inhibited
the migration of MCF-7 cells on vitronectin, in the pres-
ence and absence of uPA. These studies suggest that
uPAR or another GPI-anchored protein is critical for
MCF-7 cell migration on vitronectin. In control experi-
ments, we demonstrated that MCF-7 cell adhesion and mi-
gration on vitronectin are totally blocked by the integrin
antagonists, EDTA (1 mM) and GRGDSP (0.5 mM) (data
Table I. RLC Serine-phosphorylation in uPA-treated MCF-7 
Cells (% of Controls*)
Inhibitor 2uPA 1uPA
None 100 6 20 300 6 44
ML-7 117 6 7 115 6 12
ML-9 97 6 9 84 6 5
W-7 97 6 8 79 6 12
PD098059 80 6 17 95 6 11
*uPA treatments were for 60 min. Inhibitors were added 15 min before uPA or vehi-
cle. Serine phosphorylation is expressed as a percentage of that observed in the ab-
sence of uPA or drugs.
Figure 7. MLCK activity is criti-
cal for uPA-promoted cell mi-
gration. (A) MCF-7 cells were
treated with the specified
MLCK inhibitors and allowed to
migrate for 6 h on serum-coated
Transwell membranes. (B)
MCF-7  cells, uPAR overexpress-
ing MCF-7 cells, and HT 1080
cells were treated with ML-9 (30
mM), ML-7 (3 mM), or W-7 (51
mM), in the presence (1) or ab-
sence (2) of DIP-uPA, and al-
lowed to migrate for 6 h. Control
cells were not treated with any
of the MLCK inhibitors. Cellular
migration was expressed as a
percentage of that observed with
control cells, of the same cell
line, in the absence of DIP-uPA
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not shown). Thus, whereas uPAR apparently plays an im-
portant role in MCF-7 cell migration on vitronectin, this
process is still dependent on integrins.
aVb5 Mediates MCF-7 Cell Adhesion to Vitronectin
Meyer et al. (1998) demonstrated that MCF-7 cells express
aVb5 and aVb1, but not aVb3. Our flow cytometry experi-
ments, with antibodies directed against aVb5 and aVb3,
confirmed their results (data not shown). We also demon-
strated substantial levels of cell-surface b1 subunit; how-
ever, our antibody was not specific for aVb1. To compare
the function of various integrins in MCF-7 cell adhesion
to vitronectin, in the presence and absence of DIP-uPA
(10 nM), integrin-neutralizing antibodies were used. In the
absence of uPA, antibody P1F6, which blocks aVb5, sub-
stantially inhibited MCF-7 cell adhesion whereas LM609,
which blocks aVb3, was ineffective as anticipated (Fig.
9). Interestingly, when the b1-integrin–blocking antibody,
6S6, was added in combination with P1F6, the extent of in-
hibition was significantly increased (P , 0.05). These re-
sults suggest that a b1 subunit–containing integrin (proba-
bly aVb1) plays a significant supporting role in MCF-7 cell
adhesion to vitronectin. DIP-uPA neither promoted nor
inhibited MCF-7 cell adhesion in the presence or absence
of any of the antibodies, suggesting that uPA does not af-
fect the function of the major vitronectin-binding integrins
as mediators of MCF-7 cell adhesion.
A b1-Integrin and aVb5 Function in uPA-promoted 
MCF-7 Cell Migration
In the absence of uPA, aVb3-blocking antibody had no ef-
fect on MCF-7 cell migration on vitronectin, as anticipated
(Fig. 10 A). However, aVb5-blocking antibody was also
inactive and b1 subunit–blocking antibody inhibited mi-
gration by ,25%. When added in combination, aVb5-
blocking antibody and the b1-blocking antibody inhibited
migration by up to 79 6 5%. These results suggest that
aVb5 and a b1-containing integrin (probably aVb1) func-
tion interchangeably in MCF-7 cell migration on vitronec-
tin, in the absence of uPA.
Figure 8. uPA-promoted cellular migration is
matrix protein–selective. Transwell membranes
were coated with purified vitronectin or with
type I collagen. MCF-7 cells that were treated
with mannosamine (1) and untreated cells (2)
were allowed to migrate for 6 h in the presence of
10 nM DIP-uPA (1) or vehicle (2). Migration
was expressed as a percentage of that observed
with control cells (no mannosamine or DIP-uPA
treatment) on vitronectin-coated membranes.
Figure 9. aVb5 and b1-containing integrins medi-
ate MCF-7 cell adhesion to vitronectin. MCF-7
cells were allowed to adhere to vitronectin-
coated surfaces for 1 h in the presence (1) or ab-
sence (2) of 10 nM DIP-uPA. Some MCF-7 cells
were treated with blocking antibodies (each at 32
mg/ml) against aVb3 (LM609), aVb5 (P1F6), and/
or b1 subunit (6S6). Adherent cells were stained
with Calcein AM and measured by fluorescence
emission using a Cytofluor 2350. Cellular adhe-
sion was quantitated as a percentage of that ob-
served with control cells that were not exposed to
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Fig. 10 B compares the activities of the vitronectin-bind-
ing integrins in mediating uPA-stimulated MCF-7 cell mi-
gration. The aVb3-blocking antibody, LM609, had no
effect on the uPA response. Antibody P1F6, which neu-
tralizes aVb5, reduced the magnitude of the uPA response;
however, a statistically significant increase in cellular mi-
gration was still observed (P , 0.005). The uPA response
was reduced still further when migration was allowed to
proceed in the presence of antibody 6S6. Importantly,
when antibodies P1F6 and 6S6 were added in combina-
tion, the response of MCF-7 cells to uPA was entirely ab-
rogated. These results demonstrate that uPA-stimulated
MCF-7 cell migration on vitronectin is mediated by the
same integrins which function in the absence of uPA. A
b1-containing integrin (probably aVb1) and aVb5 are both
involved.
uPA Does Not Promote the Migration of MCF-7 Cells 
that Express aVb3
Yebra et al. (1996) demonstrated that growth factors pro-
mote pancreatic carcinoma cell migration on vitronectin
by a mechanism that is dependent on endogenously syn-
thesized uPA when the cells express aVb5 but not when
they express aVb3. To determine whether the pattern of
integrin expression influences the ability of MCF-7 cells to
respond to exogenously added uPA, MCF-7 cells were
transfected to express the b3-integrin subunit. aVb3 ex-
pression was demonstrated in cells that had been selected
in G418 for 14 d, by flow cytometry (Fig. 11 A). DIP-uPA
stimulated ERK1/2 phosphorylation in the b3-expressing
cells (Fig. 11 B). Interestingly, ERK phosphorylation was
sustained for an increased period of time (at least 40 min),
compared with the parent cell line (,5 min) (Nguyen et al.,
1998). Previous studies have shown that aVb3 may affect
the duration of ERK activation in other cell systems as
well (Elicieri et al., 1998).
aVb3-expressing MCF-7 cells demonstrated increased
migration on serum-coated membranes, in the absence of
uPA, compared with the parent cell line (control) and
MCF-7 cells which had been transfected with empty vector
(Fig. 11 C). However, DIP-uPA (10 nM) did not stimulate
migration of the aVb3-expressing cells. When LM609 was
added to block the activity of aVb3, cellular migration re-
turned to the pretransfection level; however, the cells also
regained responsiveness to DIP-uPA. Identical results
were obtained in transient transfection experiments; cells
that were cotransfected to express GFP and b3-integrin
subunit demonstrated 2.6-fold increased migration com-
pared with cells that were transfected with pEGFP alone.
However, these cells did not respond to DIP-uPA (data
not shown). Antibody LM609 decreased the migration of
the transiently transfected cells but restored responsive-
ness to uPA. These results suggest that aVb3 serves as the
dominant integrin responsible for the migration of b3-
transfected cells and that uPA does not promote aVb3-
mediated MCF-7 cell migration. When aVb3 is blocked,
the naturally occurring vitronectin-binding integrins re-
main available and the function of these integrins is en-
hanced by uPA.
aVb3-Mediated MCF-7 Cell Migration
Is MLCK-independent
Since the ability of uPA to promote MCF-7 cell migration
depends on MLCK activity, we performed experiments to
determine whether aVb3-expressing cells, which were re-
fractory to uPA stimulation, are also refractory to MLCK
inhibitors. Migration of b3-expressing cells was studied in
the presence of ML-7, ML-9, and W-7, at concentrations
that abolished the uPA response in untransfected cells. As
shown in Table II, none of the inhibitors significantly af-
fected the migration of b3-expressing MCF-7 cells on vi-
tronectin. Thus, MLCK does not play an essential role in
aVb3-mediated MCF-7 cell migration.
Discussion
Cellular migration is an integrated, multistep process which
is regulated by growth factors and extracellular matrix
proteins that bind integrins (Lauffenburger and Horwitz,
1996). The uPA/uPAR system also regulates cellular mi-
gration; this activity may reflect the ability of uPAR to
Figure 10. aVb5 and a b1-containing integrin mediate MCF-7 cell
migration in the presence and absence of uPA. (A) MCF-7 cells
were treated with increasing concentrations of blocking antibod-
ies against aVb3 (LM609), aVb5 (P1F6), and/or b1-integrin sub-
unit (6S6) and allowed to migrate for 6 h in Transwell chambers
with vitronectin-coated membranes. (B) MCF-7 cells were
treated with 10 nM DIP-uPA (1) or with vehicle (2) in the pres-
ence of the specified antibodies (32 mg/ml) and allowed to mi-
grate for 6 h on vitronectin-coated membranes. Control cells
were not treated with antibodies. Migration was expressed as a
percentage of that observed with control cells in the absence of
DIP-uPA.The Journal of Cell Biology, Volume 146, 1999 160
bind directly to vitronectin, associate with and modulate
the function of integrins, initiate cell-signaling responses,
or the function of uPA as a proteinase (Andreasen et al.,
1997; Chapman, 1997). Although uPA-deficient (2/2)
mice are viable and demonstrate only modest phenotypic
abnormalities in the absence of exogenous challenge (Car-
meliet et al., 1994), major deficiencies in cellular migration
may be observed under specific circumstances. For exam-
ple, uPA 2/2 mice demonstrate inadequate inflammatory
cell recruitment and significantly increased mortality when
challenged by pulmonary infection with Cryptococcus neo-
formans (Gyetko et al., 1996) and may also be predisposed
to other infections (Shapiro et al., 1997). Similarly, mice
that are uPAR-deficient demonstrate deficient recruit-
ment of inflammatory cells to inflamed peritoneum (May
et al., 1998).
We demonstrated previously that uPA promotes MCF-7
cell migration, in vitro, in serum-coated Transwell cham-
bers (Nguyen et al., 1998). This activity did not require
uPA proteolytic activity since the amino-terminal frag-
ment of uPA, which contains the receptor-binding domain
but lacks the serine proteinase domains, was also active.
Furthermore, uPA-promoted MCF-7 cell migration was
blocked by PD098059, leading us to hypothesize that ERK
activation is critical in the pathway by which uPA stimu-
lates cellular migration. MCF-7 cells express ,4,000 cop-
ies of cell-surface uPAR (Nguyen et al., 1998; Webb et al.,
1999), yet demonstrate increased migration when stimulated
by uPA at concentrations as low as 50 pM (Webb et al.,
1999). This may suggest that the uPAR-initiated signaling
response is exquisitely sensitive to low levels of uPAR li-
gation. However, other investigators have presented evi-
dence for the possible existence of a second cell-surface
uPA-binding site which may be involved in uPA signaling
(Koopman et al., 1998). Thus, in the present investigation,
we tested the hypothesis that uPAR ligation and ERK ac-
tivation are responsible for promoting cellular migration
in three separate model systems. In MCF-7 cells, uPAR-
overexpressing MCF-7 cells, and HT 1080 cells, uPA- and
Figure 11. MCF-7 cells which express aVb3 are refractory to
uPA-stimulation in migration assays. (A) MCF-7 cells were trans-
fected to express b3-integrin subunit. After selection for 14 d, cell-
surface aVb3 expression was detected by flow cytometry using an-
tibody LM609. Transfected cells are shown with the broken line.
The solid line shows untransfected MCF-7 cells. (B) aVb3-
expressing MCF-7 cells were treated with DIP-uPA for the speci-
fied times, with EGF (25 ng/ml) for 5 min, or with vehicle (con-
trol). Phosphorylated and total levels of ERK1/2 were
determined by immunoblot analysis. (C) aVb3-expressing MCF-7
cells (b3), untransfected cells (control), and cells that were trans-
fected with the empty vector that was used to prepare the b3-
expression construct (pBK-CMV) were treated with 10 nM DIP-
uPA (1) or with vehicle (2) and allowed to migrate for 6 h in
Transwell chambers with vitronectin-coated membranes. Migration of aVb3-expressing cells was also studied in the presence of anti-
body LM609 (32 mg/ml). Cells which penetrated the membranes were detected by Diff-Quik staining. Migration was expressed as a per-
centage of that observed with untransfected cells in the absence of DIP-uPA.
Table II. The Effects of MLCK Inhibitors on aVb3-mediated 
Cellular Migration
Transfectants Inhibitors Cell migration (% of control*)
Control None 100 6 6
b3 None 304 6 29
ML-9 (30 mM) 291 6 8
ML-7 (3 mM) 310 6 26
W-7 (50 mM) 249 6 41
*MCF-7 cell migration was quantitated as a percentage of that observed with untrans-
fected cells (control) that were not treated with inhibitors.Nguyen et al. MLCK in uPA-promoted Cellular Migration 161
uPAR-specific antibodies, which block association of uPA
with uPAR, prevented uPA-stimulated cellular migration.
PD098059 also blocked uPA-stimulated cellular migration
in all three cell lines. Thus, the ability of uPA to bind to
uPAR and activate ERK may be pivotal in promoting cel-
lular migration in different cell types with varying levels of
uPAR expression.
Although recent studies have elucidated diverse signal-
ing pathways that may be activated by uPA (Chapman,
1997), little information is available regarding the rela-
tionship of these pathways to the biological activities of
uPA such as the ability to stimulate cellular migration.
Mirashahi et al. (1997) demonstrated that uPA-stimulated
ovarian cancer cell migration depends on tyrosine kinase
activation. Using a transfection strategy that included
dominant-negative and constitutively active Ras and MEK
mutants, we have now demonstrated that these proteins
are essential for uPA-stimulated MCF-7 cell migration.
Dominant-negative H-Ras and MEK1 completely blocked
the response of MCF-7 cells to uPA. Constitutively active
H-Ras and MEK1 independently promoted MCF-7 cell
migration but also blocked the uPA response. We inter-
pret these results to mean that Ras and MEK are neces-
sary and sufficient in the pathway by which uPAR ligation
is linked to ERK activation and increased cellular migration.
Since the level of cellular migration observed in cells ex-
pressing constitutively active H-Ras or MEK1 was no
greater than that observed when control cells were treated
with DIP-uPA, the uPAR-initiated signaling cascade ap-
pears to be sufficiently potent to optimally activate the op-
erational downstream effectors of motility stimulation.
Furthermore, since the dominant-negative H-Ras and
MEK1 mutants entirely blocked uPA-stimulated cellular
migration, other uPA-signaling pathways, which do not in-
clude Ras and MEK, apparently do not affect MCF-7 cell
migration or, less likely, have offsetting activities.
In MCF-7 cells, uPA-induced ERK activation is highly
transient; however, the effects of uPA on cellular migra-
tion are sustained (Nguyen et al., 1998). Increased MCF-7
cell migration is demonstrable for at least 24 h, even when
the cells are pulse-exposed to uPA for only 30 min and
then washed. The transient nature of ERK activation may
be explained by the activity of MAP kinase phosphatases
(Clarke, 1994; Keyse, 1995) or by negative feedback loops
which limit Ras activation (Corbalan-Garcia et al., 1996).
It is also possible that activated ERK, which becomes as-
sociated with the cytoskeleton, is not completely extracted
by the detergents used in the immunoblotting experi-
ments. We demonstrated that uPA-promoted MCF-7 cell
migration does not require new gene transcription or pro-
tein synthesis. Actinomycin D and cycloheximide had no
effect on the rate of MCF-7 cell migration in 6 h, in the
presence or absence of DIP-uPA. Thus, we undertook
studies to identify ERK substrates, other than transcrip-
tion factors, that may be responsible for uPA-promoted
MCF-7 cell migration. Once activated, ERK localizes not
only to the nucleus, but also to the plasma membrane
(Gonzalez et al., 1993) and to the cytoskeleton (Reszka et al.,
1995). MLCK has been identified previously as an ERK
substrate which may be involved in stimulating cellular mi-
gration (Klemke et al., 1997). When MLCK is phosphory-
lated by ERK, the MLCK is apparently activated and thus
phosphorylates RLC in the presence of decreased concen-
trations of Ca21/calmodulin in vitro (Klemke et al., 1997).
Phosphorylation of RLC on serine-19 stimulates the actin-
activated ATPase activity of myosin-II and promotes myo-
sin-binding to filamentous actin, which drives contraction
of the actin-cytoskeleton (Lamb et al., 1988; Goeckeler
and Wysolmerski, 1995). In stationary cells, MLCK may
be involved in the formation of strong focal adhesions
and stress fibers (Chrzanowska-Wodnicka and Burridge,
1996). However, in migrating cells, MLCK probably func-
tions to enhance contraction of the cytoskeleton at the
rear of the cell and within leading lamellipodia (Cande
and Ezzell, 1986; Kolega and Taylor, 1993; Jay et al., 1995;
Moores et al., 1996; Matsumura et al., 1998).
In uPA-treated MCF-7 cells, MLCK was phosphory-
lated by a MEK-dependent pathway and remained phos-
phorylated for at least 6 h, which was the duration of our
standard Transwell migration assay. The phosphorylated
MLCK was also apparently activated since levels of ser-
ine-phosphorylated RLC increased and this increase was
prevented by ML-7 and ML-9. The same MLCK inhibitors
blocked the motility-stimulating activity of uPA in three
separate model systems. Thus, MLCK provides a link be-
tween uPAR ligation and increased cytoskeletal contrac-
tility which drives cellular migration. Although the in-
crease in RLC phosphorylation was only about two- to
threefold, our analysis was not sensitive to possible com-
partmentalization of the enzyme. Thus, it is possible that
RLC phosphorylation was increased to a much greater
level within specific regions of the cell. Since MLCK phos-
phorylation and activation are sustained in uPA-treated
cells, continuous ERK activity may not be necessary for
motility stimulation. We propose that the uPAR-activated
signaling pathway, which promotes cellular motility, in-
cludes Ras®Raf®MEK®ERK®MLCK.
In the absence of uPA, the level of phosphorylated
MLCK in MCF-7 cells was near or below the detection
limit of our assay. Furthermore, MLCK inhibitors, which
entirely blocked uPA-stimulated MCF-7 cell migration,
did not affect the level of phosphorylated RLC or cellu-
lar migration, in the absence of uPA. Similar results were
obtained in migration assays with uPAR-overexpressing
MCF-7 cells and HT 1080 cells. These results may be ex-
plained if RLC phosphorylation is stable in the time
course of our experiments, so that only new RLC phos-
phorylation is blocked by the inhibitors. However, it is
also possible that MLCK does not play a major role in reg-
ulating the basal level of RLC phosphorylation, in the ab-
sence of stimulants such as uPA, in MCF-7 and HT 1080
cells. Evidence supporting the latter hypothesis has been
reported in other systems (Mita and Walsh, 1997).
Enzymes which may phosphorylate RLC, other than
MLCK, include: Ca21/calmodulin-dependent protein ki-
nase II, Rho-associated kinase, MAP kinase–activated
protein kinases, and p21-activated protein kinase (Tan et
al., 1992; Amano et al., 1996; Komatsu et al., 1997; Eyk et
al., 1998; Bresnick, 1999).
Yebra et al. (1996) demonstrated that endogenously
synthesized uPA is required for phorbol ester- or trans-
forming growth factor-a–promoted FG cell migration. Al-
though the mechanism of uPA action was not fully charac-
terized, it is tempting to speculate that in the FG cells,The Journal of Cell Biology, Volume 146, 1999 162
endogenously synthesized uPA functioned comparably to
exogenously added uPA, as defined in the present study.
Plasminogen activator inhibitor (PAI)-1 and PAI-2 inhib-
ited FG cell migration, suggesting a role for uPA protein-
ase activity in this process (Yebra et al., 1996) and a major
difference in the mechanism of uPA activity in the FG
cells compared with the MCF-7 and HT 1080 cells. Alter-
natively, the activity of PAI-1 and PAI-2, in the FG cell
system, may reflect the ability of these proteinase inhibi-
tors to influence cellular catabolism of endogenously pro-
duced uPA and thereby alter the concentration of uPA
which is available to ligate uPAR (Conese et al., 1995;
Webb et al., 1999).
aVb3 mediates cellular migration in the absence of exog-
enous stimulants whereas aVb5 may mediate cellular mi-
gration only in cells that are treated with growth factors
such as EGF or insulin-like growth factor-1 (Klemke et al.,
1994; Filardo et al., 1996; Brooks et al., 1997). Since the
uPA-signaling pathway defined here is similar to that trig-
gered by many growth factors, we undertook studies to de-
termine whether the ability of uPA to promote cellular mi-
gration depends on the integrins which are functional.
Initially, we identified a substratum selectivity; uPA pro-
moted cellular migration on vitronectin but not type I col-
lagen. We then demonstrated that uPA functions to pro-
mote cellular migration on vitronectin only when certain
integrins are functional. In the parent MCF-7 cells, aVb5
and a b1 subunit containing integrin (probably aVb1) medi-
ated cellular migration. When these cells were transfected
to express aVb3, the cells still responded to uPA, as deter-
mined in ERK phosphorylation experiments; however,
uPA no longer stimulated cellular migration. Further-
more, MLCK antagonists did not inhibit the migration
of aVb3-expressing cells. Thus, the Ras/ERK-dependent
uPAR-signaling pathway may not promote motility in
uPA-treated cells that utilize aVb3 to migrate on vitronec-
tin. Interestingly, despite expression of aVb3 in the trans-
fected cells, alternative vitronectin-binding integrins were
still available and competent to mediate cellular migration
when aVb3 was blocked with antibody. Under these condi-
tions, the ability of uPA to promote cellular migration was
restored.
HT 1080 cells express substantial levels of aVb5 and uti-
lize this integrin, as opposed to aVb3, to adhere and mi-
grate on vitronectin (Conforti et al., 1994, and our unpub-
lished results). Thus, the ability of uPA to promote HT
1080 cell migration on vitronectin by a RAS/ERK-depen-
dent pathway is consistent with the pattern of vitronectin-
receptor expression in this cell line. In each of our model
systems, we focused our studies on the response to exog-
enously added uPA and consistently demonstrated a
dominant role of uPAR-initiated signaling in mediating
changes in cellular motility. However, we also obtained
evidence for uPA-independent uPAR activities which
may affect cellular migration. First, uPAR-overexpressing
MCF-7 cells demonstrated increased migration on vi-
tronectin in the absence of exogenously added uPA. Since
MCF-7 cells express very low levels of uPA (Nguyen et al.,
1998; Webb et al., 1999) and the increase in migration
was not blocked by uPA-specific antibody or PD098059,
uPAR overexpression apparently increased basal MCF-7
cell migration by a uPA-independent mechanism. Sec-
ondly, mannosamine treatment inhibited MCF-7 cell mi-
gration on vitronectin, in the presence and absence of ex-
ogenously added uPA. These uPA-independent uPAR
activities may be related to the ability of uPAR to bind vi-
tronectin or modulate integrin function (Wei et al., 1994,
1996).
The reason why uPA-promoted activation of ERK and
MLCK stimulates cellular migration in an integrin-selec-
tive manner remains to be determined. Various integrin
properties, including their subcellular localization, avidity
for ligand, and strength of focal adhesions may be in-
volved. The ability of uPA to regulate RLC phosphoryla-
tion, as well as integrin function (results presented here
and by Wei et al., 1996), suggests a model in which uPA
and uPAR orchestrate diverse aspects of cellular migra-
tion.
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